Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea

被引:0
|
作者
Jung Wan Park
Hyungmin Lee
Jung Wook Kim
Bongyoung Kim
机构
[1] Korea Centers for Disease Control and Prevention,Department of Healthcare
[2] Asan Medical Center,Associated Infection Control
[3] University of Ulsan College of Medicine,Department of Infectious Diseases
[4] Center for Infectious Diseases Research,Division of Antimicrobial Resistance
[5] Korea National Institute of Health,Department of Internal Medicine
[6] Korea Centers for Disease Control and Prevention,undefined
[7] Hanyang University College of Medicine,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the present study was to describe the characteristics of infections with Staphylococcus aureus with reduced vancomycin susceptibility (SARVS) including vancomycin-intermediate S. aureus (VISA) in South Korea, using data from the national sentinel surveillance system during 2014–2016. A total of 66 patients infected or colonized with SA-RVS were reported using the sentinel surveillance system. Among them, VISA was confirmed in 14 isolates (21.2%) and no vancomycin-resistant S. aureus (VRSA) was detected. Most of patients had any kind of indwelling devices (81.8%, 54/66) and underwent surgical procedures in the previous 6 months (84.8%, 56/66). Patients who admitted to an intensive care unit (ICU) in the previous 3 months were 68.2% (45/66). Furthermore, patients who used vancomycin or had MRSA in the previous 1 month were 54.5% (36/66) and 59.1% (39/66), respectively. Upon review of the medical records, 54.5% (36/66) of patients were classified as having SA-RVSassociated infection and 30-day mortality was 19.4% (7/36). Our findings revealed that there was no VRSA in South Korea. SA-RVS including VISA existed particularly in patients who had indwelling devices, history of surgical procedure, and history of ICU admission.
引用
收藏
相关论文
共 50 条
  • [31] Reduced Susceptibility to Vancomycin in Staphylococcus aureus Response
    Maria Aguado, Jose
    San-Juan, Rafael
    Lalueza, Antonio
    Sanz, Francisca
    Rodriguez-Otero, Joaquin
    Gomez-Gonzalez, Carmen
    Chaves, Fernando
    EMERGING INFECTIOUS DISEASES, 2011, 17 (11) : 2084 - 2084
  • [32] A Novel δ-Hemolysis Screening Method for Detecting Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate S-aureus
    Cafiso, V.
    Bertuccio, T.
    Spina, D.
    Purrello, S.
    Blandino, G.
    Stefani, Stefania
    JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (05) : 1742 - 1744
  • [33] Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure
    Kelley, Peter G.
    Gao, Wei
    Ward, Peter B.
    Howden, Benjamin P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (05) : 1057 - 1060
  • [34] The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC
    Chen, Hongbin
    Liu, Yudong
    Sun, Wenjia
    Chen, Minjun
    Wang, Hui
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2011, 71 (03) : 301 - 303
  • [35] Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia
    Naimi, TS
    Anderson, D
    O'Boyle, C
    Boxrud, DJ
    Johnson, SK
    Tenover, FC
    Lynfield, R
    CLINICAL INFECTIOUS DISEASES, 2003, 36 (12) : 1609 - 1612
  • [36] Detection of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus among Methicillin-Resistant Staphylococcus aureus
    Chaudhary, Bajarangi Lal
    Bisht, Dakshina
    Faujdar, Sameer
    ASIAN JOURNAL OF PHARMACEUTICAL RESEARCH AND HEALTH CARE, 2022, 14 (01) : 16 - 20
  • [37] Clinical and Molecular Characterization of Invasive Heteroresistant Vancomycin-Intermediate Staphylococcus aureus Infections in Korean Hospitals
    Kim, Eu Suk
    Bae, In-Gyu
    Cho, Jeong Eun
    Choi, Yun Jung
    Kim, Il-Hwan
    Kang, Gi-Su
    Sin, Hye-yun
    Song, Kyoung-Ho
    Park, Chulmin
    Lee, Dong-Gun
    Kim, Moonsuk
    Park, Kyoung Un
    Kim, Hong Bin
    JOURNAL OF CLINICAL MICROBIOLOGY, 2016, 54 (03) : 760 - 763
  • [38] Oxidative stress resistance and fitness-compensatory response in vancomycin-intermediate Staphylococcus aureus (VISA)
    Tan, Xin-Ee
    Neoh, Hui-min
    Cui, Longzhu
    Hiramatsu, Keiichi
    Jamal, Rahman
    CANADIAN JOURNAL OF MICROBIOLOGY, 2019, 65 (08) : 623 - 628
  • [39] Emergence of vancomycin-intermediate resistant Staphylococcus aureus in north of Palestine
    Adwan, Ghaleb
    Abu-Shanab, Bassam
    Odeh, Marwan
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2009, 2 (05) : 44 - 48
  • [40] Novel Combinations of Vancomycin plus Ceftaroline or Oxacillin against Methicillin-Resistant Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA
    Werth, B. J.
    Vidaillac, C.
    Murray, K. P.
    Newton, K. L.
    Sakoulas, G.
    Nonejuie, P.
    Pogliano, J.
    Rybak, M. J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (05) : 2376 - 2379